Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.42 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.42 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.42 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.42 |
| ▸ | BCL2 | P10415 | 5/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333553 | 0.88 | USP14 (0.45) | PTGESMDM2BCL2MCL1PPARG | |
| SCHEMBL333981 | 0.88 | MDM2 (0.44) | PTGESMDM2BCL2MCL1PPARG | |
| SCHEMBL335133 | 0.85 | PTPN11 (0.42) | PTGESTEAD1TEAD4TEAD2TEAD3 | |
| SCHEMBL334015 | 0.85 | KMT2A (0.43) | PTGESMDM2BCL2MCL1KMT2A | |
| SCHEMBL1407250 | 0.85 | PPARG (0.51) | PTGESPPARGPPARA | |
| SCHEMBL333886 | 0.84 | RXRA (0.45) | PTGESMDM2BCL2MCL1PPARG | |
| SCHEMBL333738 | 0.82 | PPARG (0.48) | PTGESPPARGPPARA | |
| SCHEMBL334349 | 0.82 | PPARG (0.44) | PTGESPPARGPPARAKMT2A | |
| SCHEMBL333811 | 0.80 | PPARG (0.50) | PTGESPPARGPPARA | |
| SCHEMBL27717578 | 0.80 | USP14 (0.45) | PPARGKMT2ARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097623-B2 | 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics | BIOLIPOX AB (SE) | 2012-01-17 | — | — | US | disclosed |
| EP-1841735-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1841735-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077366-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | PTGES 34/4885TEAD1 1337/4885TEAD4 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.